Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Completed 9Recruiting 2Terminated 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Thoracic 1Breast 1

Conditions

Multiple Myeloma 87Precursor Cell Lymphoblastic Leukemia-Lymphoma 21Recurrence 16Burkitt Lymphoma 13Neoplasms 10Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Leukemia, Biphenotypic, Acute 7Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 6Lung Neoplasms 6Immunoglobulin Light-chain Amyloidosis 6Neoplasms, Plasma Cell 5Hodgkin Disease 5Smoldering Multiple Myeloma 4Leukemia 4Carcinoma, Non-Small-Cell Lung 4Waldenstrom Macroglobulinemia 3Triple Negative Breast Neoplasms 3Prostatic Neoplasms 3Neoplasm Metastasis 3Nausea 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma 3Brain Neoplasms 3Renal Insufficiency 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Ovarian Neoplasms 2Lymphoma, T-Cell, Peripheral 2Lymphoma, T-Cell 2Lymphoma, B-Cell 2Leukemia, Plasma Cell 2

Interventions

Bevacizumab 41Paclitaxel 35Carboplatin 29pembrolizumab 22Specimen Handling 14Cisplatin 14Cyclophosphamide 13olaparib 12Blood Specimen Collection 11niraparib 10fludarabine 9Magnetic Resonance Spectroscopy 9Drug Therapy 9liposomal doxorubicin 8Topotecan 8Taxes 8Gemcitabine 8Fulvestrant 8Biopsy 8Doxorubicin 6cemiplimab 5abemaciclib 5Surveys and Questionnaires 5Standard of Care 5Injections 5Fluorouracil 5Cytoreduction Surgical Procedures 5trastuzumab deruxtecan 4mirvetuximab soravtansine 4aldesleukin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Ovarian Neoplasms × Dexamethasone × Clear all
NCT06824467 2026-05-08

TroFuse-022

Merck Sharp & Dohme LLC

Phase 3 Recruiting
770 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04300556 2026-03-13

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

Eisai Inc.

Phase 1/2 Recruiting
182 enrolled
BreastGynecologicThoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡